Fig. 6.
8‐Cl‐Ado enhances the antileukemic effect of VEN in vivo. MV4-11‐Luc AML cells (5 × 106) were i.v.-injected in NSG mice 7 days before start of treatment with vehicle control, 50 mg/kg/day 8-Cl-Ado (daily), 20 mg/kg/day VEN (5 days per week) or 8-Cl-Ado plus VEN. a Bioluminescence images obtained on days 5 and 21. b Left, Tumor burden on day 21, as assessed by analysis of bioluminescence images. Right, Average weight of animals obtained on days 5 and 21. c Days of survival were quantified using the Kaplan–Meier log rank survival test